



PRESS RELEASE

AgenT Unveils Groundbreaking Multiomics Blood Tests for Early Alzheimer's Detection at AAIC 2023

July 27, 2023 5:00 PM Central European Time

PARIS, France – AgenT, a life sciences company whose mission is to detect Alzheimer's early through a simple blood test, is thrilled to announce the final results from its multi-center retrospective APOLLO study which evaluated two blood tests to diagnose Alzheimer's in the pre-dementia stages in 632 individuals coming from 7 independent cohorts across the globe (USA, Europe, Australia). Results were presented in two posters at the Alzheimer's Association International Conference (AAIC) 2023 in Amsterdam.

"The recent FDA approval of Eisai's Leqembi marks a historic turning point in Alzheimer's disease management, offering tangible hope to slow cognitive decline. However, with a high annual cost that can reach approximately \$26,500 per patient, complex administration, and significant side effects, the need for precision medicine has never been more crucial. Current diagnostic tools, such as PET imaging and lumbar puncture, are invasive, expensive, and yield up to 30% false positives. Moreover, the blood tests under development use the same biomarkers (Abeta or pTau) and therefore present the same limitations," said Baptiste Billoir, co-founder and CFO at AgenT.

"Hence, it's imperative that we expedite the validation of new blood biomarkers for Alzheimer's. Our aim is to facilitate highly specific detection from the asymptomatic stage, laying the groundwork for a personalized approach to Alzheimer's care. This was the exact intent behind our APOLLO study," shared Dr. Jérôme Braudeau, co-founder and CEO at AgenT.

The APOLLO study represents the culmination of a decade of intense research. The process started with the pre-identification of new Alzheimer's biomarkers in a gene-transfer based animal model. Subsequently, the team verified the diagnostic relevance of these biomarkers in humans using two European cohorts. Finally, this rigorous research journey culminated in the

successful development of two cutting-edge diagnostic tests, all made possible by a retrospective study across seven distinct cohorts (USA, Europe, Australia), each clinically monitored over several years.

AgenT's first poster, [*Multiomics Blood Biomarkers Predict Alzheimer's From Predementia with High Specificity*](#), introduces the B-HEALED™ test, a pioneering diagnostic tool specifically designed for the early detection of prodromal Alzheimer's disease (AD) in individuals aged 55 and older experiencing mild cognitive impairment (MCI). B-HEALED is powered by a proprietary 19 multiomics biomarkers panel quantified through mass spectrometry and interpreted by an advanced machine learning algorithm. In the external validation (n=109), B-HEALED achieved 92.0% specificity in predicting AD patients (prodromal AD and demented AD) from non-AD Brain Disorders patients, with 52.4% sensitivity. This test offers unparalleled accuracy, reducing the false positive rate by 3-fold compared to current diagnostics like amyloid PET and CSF assays.

"This test is not just a step, but a significant leap forward in Alzheimer's diagnosis and patient selection. It could accurately identify a primarily prodromal AD patient population suitable for clinical trial recruitment. Additionally, it could aid in selecting MCI patients for anti-amyloid drug prescription, substantially improving the benefit-risk ratio by significantly reducing false positives, compared to relying solely on amyloid deposit-related tests," explained Dr. Benoît Souchet, CSO at AgenT.

AgenT's second poster, [*Multiomics Blood Test for Increasing Asymptomatic AD Patients Proportion in Preventive Clinical Trials*](#), introduces the B-AHEAD™ test, a pioneering diagnostic tool specifically designed for the early detection of asymptomatic Alzheimer's disease (AD) in individuals aged 55 and older without any cognitive impairment. B-AHEAD is powered by a proprietary 20 multi-omics biomarkers panel quantified through mass spectrometry and interpreted by an advanced machine learning algorithm. In the external validation (n=88), B-AHEAD achieved 81.9% specificity in predicting asymptomatic AD patients from healthy controls, with 56.3% sensitivity.

"This groundbreaking test marks a significant leap in facilitating the inclusion of true asymptomatic Alzheimer's patients in preventative clinical trials. By enhancing the statistical robustness of these trials, it opens up unprecedented possibilities for demonstrating the effectiveness of early-stage disease interventions," commented Dr Alkéos Michail, CTO at AgenT.

These two diagnostic tools are already accessible as Research Use Only products, serving patient inclusion in clinical trials. Concurrently, they are undergoing industrialization for broader distribution, paving the way for accessibility to the general population. "As Alzheimer's stands on the cusp of

a transformative era marked by the emergence of treatments targeting multiple disease-related biological pathways, it's essential to deepen our understanding of the disease and refine the tools for precision medicine. These latest results underscore AgenT's capability to stand at the forefront of this monumental shift in healthcare," stated Jérôme Braudeau.

About AgenT

AgenT is a life sciences company whose mission is to defeat Alzheimer's by targeting the silent phase. By combining multi-omics assays with advanced machine learning techniques, they found new blood biomarkers deregulated from the earliest stages of the disease. Using this proprietary database, they are developing an accurate blood diagnosis and the next generation of precision therapies to treat Alzheimer's. Agent is headquartered in Paris, France.

For more information about AgenT, please visit www.agent-biotech.com.

Contact:

Jérôme Braudeau
Jerome.braudeau@agent-biotech.com
+33 6 11 10 26 95

About AAIC

The Alzheimer's Association International Conference is the largest and most influential international meeting dedicated to advancing dementia science. Each year, AAIC convenes the world's leading basic science and clinical researchers, next-generation investigators, clinicians, and the care research community to share research discoveries that will lead to methods of prevention and treatment and improvements in the diagnosis of Alzheimer's disease.

For more information about AAIC, please visit <https://www.alz.org/aaic/overview.asp>.